There are similarities and differences between the REDUCE-IT and BETonMACE trials, patient populations, patient risk factors, etc. I've rambled on about this stuff enough in the past. I'm not going to repeat myself. Keep in mind that Vascepa is primarily indicated for those with elevated triglycerides; though that may change depending on Amarin's update to its label to be filed with the FDA soon. A successful BETonMACE is all that matters right now. Worry about competition with other drugs later. There will always be competition.

BearDownAZ